AKESO Shares Surge Over 7% in Morning Session on Clinical Approval for Cadonilimab in Colon Cancer

Stock News

May 21

AKESO (09926) saw its shares rise more than 7% in morning trading. As of the latest update, the stock was up 5.04%, trading at HK$120.8 with a turnover of HK$690 million. The catalyst for the move is news from the CDE website indicating that AKESO's clinical trial application for Cadonilimab injection, filed under registration category 2.2, has received implicit approval. The intended indication is for AK104 monotherapy as a neoadjuvant/adjuvant treatment for resectable high microsatellite instability (MSI-H) or mismatch repair deficient (dMMR) colon cancer. This marks the entry of this globally first-in-class PD-1/CTLA-4 bispecific antibody drug into the field of perioperative treatment for colon cancer. Cadonilimab is recognized as the world's first PD-1/CTLA-4 bispecific tumor immunotherapy drug. It initially received market approval in June 2022 for the treatment of recurrent or metastatic cervical cancer in patients who had failed prior platinum-based chemotherapy, addressing an unmet need in immunotherapy for advanced cervical cancer in China. To date, the intravenous formulation of Cadonilimab has secured approval for three indications within the domestic market.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1162071113"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1162071113\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1162071113?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-21 10:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1162071113","market":"nz","top_or_hot":-1,"title":"AKESO Shares Surge Over 7% in Morning Session on Clinical Approval for Cadonilimab in Colon Cancer","media":"Stock News","content":"<p>AKESO (09926) saw its shares rise more than 7% in morning trading. As of the latest update, the stock was up 5.04%, trading at HK$120.8 with a turnover of HK$690 million. The catalyst for the move is news from the CDE website indicating that AKESO's clinical trial application for Cadonilimab injection, filed under registration category 2.2, has received implicit approval. The intended indication is for AK104 monotherapy as a neoadjuvant/adjuvant treatment for resectable high microsatellite instability (MSI-H) or mismatch repair deficient (dMMR) colon cancer. This marks the entry of this globally first-in-class PD-1/CTLA-4 bispecific antibody drug into the field of perioperative treatment for colon cancer. Cadonilimab is recognized as the world's first PD-1/CTLA-4 bispecific tumor immunotherapy drug. It initially received market approval in June 2022 for the treatment of recurrent or metastatic cervical cancer in patients who had failed prior platinum-based chemotherapy, addressing an unmet need in immunotherapy for advanced cervical cancer in China. To date, the intravenous formulation of Cadonilimab has secured approval for three indications within the domestic market.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AKESO Shares Surge Over 7% in Morning Session on Clinical Approval for Cadonilimab in Colon Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAKESO Shares Surge Over 7% in Morning Session on Clinical Approval for Cadonilimab in Colon Cancer\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-05-21 10:52</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>AKESO (09926) saw its shares rise more than 7% in morning trading. As of the latest update, the stock was up 5.04%, trading at HK$120.8 with a turnover of HK$690 million. The catalyst for the move is news from the CDE website indicating that AKESO's clinical trial application for Cadonilimab injection, filed under registration category 2.2, has received implicit approval. The intended indication is for AK104 monotherapy as a neoadjuvant/adjuvant treatment for resectable high microsatellite instability (MSI-H) or mismatch repair deficient (dMMR) colon cancer. This marks the entry of this globally first-in-class PD-1/CTLA-4 bispecific antibody drug into the field of perioperative treatment for colon cancer. Cadonilimab is recognized as the world's first PD-1/CTLA-4 bispecific tumor immunotherapy drug. It initially received market approval in June 2022 for the treatment of recurrent or metastatic cervical cancer in patients who had failed prior platinum-based chemotherapy, addressing an unmet need in immunotherapy for advanced cervical cancer in China. To date, the intravenous formulation of Cadonilimab has secured approval for three indications within the domestic market.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2476274720.SGD","symbol_name":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"AT\" (SGDHDG) ACC","start_time":0,"source_url":"","article_id":"1162071113","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1162071113","pubTimestamp":1779331976,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"AKESO (09926) saw its shares rise more than 7% in morning trading. As of the latest update, the stock was up 5.04%, trading at HK$120.8 with a turnover of HK$690 million. The catalyst for the move is...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2476274720.SGD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"AT\" (SGDHDG) ACC","BK1161":"生物科技","LU0348766576.USD":"ALLIANZ LITTLE DRAGONS \"A\" (USD) INC","LU0417516571.SGD":"Allianz Oriental Income Cl AT Acc SGD","LU0348767384.USD":"ALLIANZLITTLE DRAGONS \"A\" (USD) ACC","IE00BPRC5H50.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) INC","LU0348827113.USD":"ALLIANZ RCM CHINA \"AT\" ACC","BK4585":"ETF&股票定投概念","LU0417516738.SGD":"Allianz Hong Kong Equity AT Acc SGD","09926":"康方生物","LU0348735423.USD":"ALLIANZ HONG KONG EQUITY \"A\" (USD) INC","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","LU0540923850.HKD":"ALLIANZ HONG KONG EQUITY \"A\" (HKD) INC","VXUS":"国际股票ETF-Vanguard","LU1720050803.USD":"安联全方位中国股票基金","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","BK1574":"生物医药B类股","LU0634319403.HKD":"ALLIANZ HONG KONG EQUITY \"AT\" (HKD) ACC","LU1961090484.USD":"ALLIANZ ALL CHINA EQUITY \"A\" (USD) INC","LU0417516902.SGD":"Allianz China Equity Cl AT Acc SGD","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","BK4588":"碎股","LU0348825331.USD":"ALLIANZ CHINA EQUITY \"A\" (USD) INC","LU2476274308.USD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"AT\" (USD) ACC","LU0348783233.USD":"安联东方收入型 CI A Dis美元","LU2399975544.HKD":"ALLIANZ ALL CHINA EQUITY \"AT\" (HKD) ACC","LU0348784397.USD":"ALLIANZ ORIENTAL INCOME \"A\" (USD) ACC","LU1794554557.SGD":"Allianz All China Equity AT Acc H2-SGD","LU2778985437.USD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"A\" (USD) INC","LU0561508036.HKD":"ALLIANZ CHINA EQUITY \"A\" (HKD) INC"},"translate_title":"卡多尼单抗治疗结肠癌获批，康方生物股价早盘飙升逾7%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VXUS":1,"09926":1},"content_text":"AKESO (09926) saw its shares rise more than 7% in morning trading. As of the latest update, the stock was up 5.04%, trading at HK$120.8 with a turnover of HK$690 million. The catalyst for the move is news from the CDE website indicating that AKESO's clinical trial application for Cadonilimab injection, filed under registration category 2.2, has received implicit approval. The intended indication is for AK104 monotherapy as a neoadjuvant/adjuvant treatment for resectable high microsatellite instability (MSI-H) or mismatch repair deficient (dMMR) colon cancer. This marks the entry of this globally first-in-class PD-1/CTLA-4 bispecific antibody drug into the field of perioperative treatment for colon cancer. Cadonilimab is recognized as the world's first PD-1/CTLA-4 bispecific tumor immunotherapy drug. It initially received market approval in June 2022 for the treatment of recurrent or metastatic cervical cancer in patients who had failed prior platinum-based chemotherapy, addressing an unmet need in immunotherapy for advanced cervical cancer in China. To date, the intravenous formulation of Cadonilimab has secured approval for three indications within the domestic market.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}